Hypera SA (HYPMY) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 26 250 sessions, November 6, 2025 to November 6, 2026
- Largest daily move
- -26.9% close of October 26, 2026
- 1-year change
- -12.2% closing prices, November 6, 2025 to November 6, 2026
- 1-month change
- -24.9% closing prices, October 6, 2026 to November 6, 2026
Company Description
Hypera SA (OTC: HYPMY) is classified in the drug manufacturers - specialty & generic industry within the Healthcare sector and carries a market capitalization of $2.8B.
HYPMY has declined 12.2% over the past year. The last closing price was $4.02.
This page collects what Stock Titan holds for HYPMY, including price data, latest news, and short interest trends.
Stock Performance
Hypera SA (HYPMY) closed at $4.02 on November 6, 2026. Over the past 12 months, the price has lost 12.2%.
HYPMY Metrics & Rankings
Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Hypera SA has 3 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, acquisition. View all HYPMY news →
SEC Filings
Short Interest History
Short interest in Hypera SA (HYPMY) currently stands at 1.7 thousand shares, down 60.7% from the previous reporting period, representing 0.0% of the float. Since November 2025, short interest has decreased by 65.4%.
Days to Cover History
Days to cover for Hypera SA (HYPMY) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 1.9 days.
HYPMY Company Profile & Sector Positioning
Hypera SA (HYPMY) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing HYPMY often look at related companies in the same sector, including Almirall SA (ALMRY), Curaleaf Holdings Inc (CURLF), Hikma Pharms PLC (HKMPY), Hikma Pharmaceuticals PLC (HKMPF), and Sumitomo Pharma Co (SMDPY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HYPMY's relative position within its industry.